These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 27823564)

  • 21. Chemical Synthesis, Biological Evaluation, and Cheminformatics Analysis of a Group of Chlorinated Diaryl Sulfonamides: Promising Inhibitors of Cholesteryl Ester Transfer Protein.
    Abu Khalaf R; Lafi A; Hajjo R; Al-Sha'er MA
    Curr Comput Aided Drug Des; 2024 Feb; ():. PubMed ID: 38424428
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Design, synthesis and biological evaluation of novel cholesteryl ester transfer protein inhibitors bearing a cycloalkene scaffold.
    Liu C; Luo C; Hao L; Wu Q; Xie H; Zhao S; Hao C; Zhao D; Cheng M
    Eur J Med Chem; 2016 Nov; 123():419-430. PubMed ID: 27490022
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Thyroid hormone increases plasma cholesteryl ester transfer protein activity and plasma high-density lipoprotein removal rate in transgenic mice.
    Berti JA; Amaral ME; Boschero AC; Nunes VS; Harada LM; Castilho LN; Oliveira HC
    Metabolism; 2001 May; 50(5):530-6. PubMed ID: 11319713
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identification of a novel, non-tetrahydroquinoline variant of the cholesteryl ester transfer protein (CETP) inhibitor torcetrapib, with improved aqueous solubility.
    Kalgutkar AS; Frederick KS; Hatch HL; Ambler CM; Perry DA; Garigipati RS; Chang GC; Lefker BA; Clark RW; Morehouse LA; Francone O; Hu X
    Xenobiotica; 2014 Jul; 44(7):591-605. PubMed ID: 24380613
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bexarotene induces dyslipidemia by increased very low-density lipoprotein production and cholesteryl ester transfer protein-mediated reduction of high-density lipoprotein.
    de Vries-van der Weij J; de Haan W; Hu L; Kuif M; Oei HL; van der Hoorn JW; Havekes LM; Princen HM; Romijn JA; Smit JW; Rensen PC
    Endocrinology; 2009 May; 150(5):2368-75. PubMed ID: 19147676
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhibition of cholesteryl ester transfer protein increases cholesteryl ester content of large HDL independently of HDL-to-HDL homotypic transfer: in vitro vs in vivo comparison using anacetrapib and dalcetrapib.
    Johns DG; Chen Y; Wang SP; Castro-Perez J; Previs SF; Roddy TP
    Eur J Pharmacol; 2015 Sep; 762():256-62. PubMed ID: 26049012
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Synthesis, biological evaluation and SAR studies of ursolic acid 3β-ester derivatives as novel CETP inhibitors.
    Chen C; Sun R; Sun Y; Chen X; Li F; Wen X; Yuan H; Chen D
    Bioorg Med Chem Lett; 2020 Jan; 30(2):126824. PubMed ID: 31780304
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Enhanced cholesteryl ester transfer protein activities and abnormalities of high density lipoproteins in familial hypercholesterolemia.
    Inazu A; Koizumi J; Mabuchi H; Kajinami K; Takeda R
    Horm Metab Res; 1992 Jun; 24(6):284-8. PubMed ID: 1634194
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Selective CETP inhibition and PPARalpha agonism increase HDL cholesterol and reduce LDL cholesterol in human ApoB100/human CETP transgenic mice.
    Hansen MK; McVey MJ; White RF; Legos JJ; Brusq JM; Grillot DA; Issandou M; Barone FC
    J Cardiovasc Pharmacol Ther; 2010 Jun; 15(2):196-202. PubMed ID: 20332533
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cholesteryl ester transfer protein inhibition in cardiovascular risk management: ongoing trials will end the confusion.
    Kappelle PJ; van Tol A; Wolffenbuttel BH; Dullaart RP
    Cardiovasc Ther; 2011 Dec; 29(6):e89-99. PubMed ID: 20645987
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Discovery of pentacyclic triterpene 3β-ester derivatives as a new class of cholesterol ester transfer protein inhibitors.
    Chen D; Huang X; Zhou H; Luo H; Wang P; Chang Y; He X; Ni S; Shen Q; Cao G; Sun H; Wen X; Liu J
    Eur J Med Chem; 2017 Oct; 139():201-213. PubMed ID: 28802120
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The potential of cholesteryl ester transfer protein as a therapeutic target.
    Gautier T; Masson D; Lagrost L
    Expert Opin Ther Targets; 2016; 20(1):47-59. PubMed ID: 26212254
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anacetrapib, a cholesterol ester transfer protein (CETP) inhibitor for the treatment of atherosclerosis.
    Masson D
    Curr Opin Investig Drugs; 2009 Sep; 10(9):980-7. PubMed ID: 19705341
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Update on the discovery and development of cholesteryl ester transfer protein inhibitors for reducing residual cardiovascular risk.
    Mantlo NB; Escribano A
    J Med Chem; 2014 Jan; 57(1):1-17. PubMed ID: 23941686
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Investigational CETP antagonists for hyperlipidemia and atherosclerosis prevention.
    Sirtori CR
    Expert Opin Investig Drugs; 2011 Nov; 20(11):1543-54. PubMed ID: 21961529
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tetrazole and ester substituted tetrahydoquinoxalines as potent cholesteryl ester transfer protein inhibitors.
    Eary CT; Jones ZS; Groneberg RD; Burgess LE; Mareska DA; Drew MD; Blake JF; Laird ER; Balachari D; O'Sullivan M; Allen A; Marsh V
    Bioorg Med Chem Lett; 2007 May; 17(9):2608-13. PubMed ID: 17331716
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Design, Synthesis and Biological Evaluation of N,N-Substituted Amine Derivatives as Cholesteryl Ester Transfer Protein Inhibitors.
    Wang X; Hao L; Xu X; Li W; Liu C; Zhao D; Cheng M
    Molecules; 2017 Oct; 22(10):. PubMed ID: 28972557
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The controversy over the use of cholesteryl ester transfer protein inhibitors: is there some light at the end of the tunnel?
    Quintão EC
    Eur J Clin Invest; 2016 Jun; 46(6):581-9. PubMed ID: 26992444
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cholesteryl ester transfer between lipoproteins does not require a ternary tunnel complex with CETP.
    Lauer ME; Graff-Meyer A; Rufer AC; Maugeais C; von der Mark E; Matile H; D'Arcy B; Magg C; Ringler P; Müller SA; Scherer S; Dernick G; Thoma R; Hennig M; Niesor EJ; Stahlberg H
    J Struct Biol; 2016 May; 194(2):191-8. PubMed ID: 26876146
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Virtual screening for natural CETP inhibitors by structure-based pharmacophore].
    Huo XQ; Qiao LS; Jiang LD; He YS; Li GY; Zhang YL
    Zhongguo Zhong Yao Za Zhi; 2015 Aug; 40(15):3063-7. PubMed ID: 26677712
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.